CYBREXA THERAPEUTICS
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and it will greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.
CYBREXA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2017-01-01
Address:
New Haven, Connecticut, United States
Country:
United States
Website Url:
http://www.cybrexa.com
Total Employee:
1+
Status:
Active
Contact:
+1 860 717 2731
Total Funding:
44.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Wordpress Plugins
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Remedy Plan Therapeutics
Remedy Plan is a pre-clinical cancer therapeutics company developing first-in-class small molecule drugs that differentiate cancer cells.
Current Advisors List
Current Employees Featured
Founder
Investors List
Elm Street Ventures
Elm Street Ventures investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Series B - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Cycle Venture Partners
Cycle Venture Partners investment in Series B - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Series B - Cybrexa Therapeutics
Advantage Capital
Advantage Capital investment in Debt Financing - Cybrexa Therapeutics
HighCape Partners
HighCape Partners investment in Series B - Cybrexa Therapeutics
Connecticut Innovations
Connecticut Innovations investment in Series B - Cybrexa Therapeutics
Official Site Inspections
http://www.cybrexa.com
- Host name: 104.21.49.15
- IP address: 104.21.49.15
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Cybrexa Therapeutics"
About - Cybrexa Therapeutics
Dr. Houston is President and Chief Executive Officer of Arvinas, Inc. Previously, he was the SVP of Specialty Discovery at Bristol-Myers Squibb (BMS). He spent more than 18 yearsSee details»
Cybrexa Therapeutics - Crunchbase Company Profile & Funding
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor …See details»
Cybrexa, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Cybrexa investors include Advantage Capital Connecticut, Connecticut Innovations, Elm Street Ventures and HighCape Capital. It is on a mission to create therapeutics that revolutionize the …See details»
Cybrexa Therapeutics Company Profile 2024: Valuation, Funding ...
Cybrexa Therapeutics General Information Description. Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeutics …See details»
Cybrexa Therapeutics - Contacts, Employees, Board Members
Organization. Cybrexa Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of …See details»
Cybrexa Therapeutics Announces Positive Final Data at ESMO …
Sep 16, 2024 Cybrexa Therapeutics. Data demonstrate broad activity of CBX-12 across six tumor types with a strong response rate in TOP1-naïve patients with ovarian (40%; N=10) and …See details»
Cybrexa raises $13.4M for first cancer drug trials
A New Haven biotech developing drugs that send cancer-fighting agents directly into tumor cells while sparing healthy tissue said it has raised $13.4 million. Cybrexa Therapeutics said it will …See details»
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration ...
CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitor Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building …See details»
Cybrexa Therapeutics Announces Data Demonstrating Early …
Oct 26, 2021 CBX-12, Cybrexa’s lead therapeutic candidate for solid tumors, demonstrates anti-tumor activity and robust efficacy signals in a heavily pretreated patient populationCBX-12 and …See details»
Cybrexa Therapeutics Announces Data Demonstrating Early
Oct 26, 2021 Cybrexa was founded by physician-scientists and has an experienced management team that has built numerous successful life sciences companies. For more …See details»
Cybrexa Regains Rights to CBX-12 - Yahoo Finance
Feb 6, 2024 Full rights returned to Cybrexa for CBX-12 effective April 25, 2024NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage …See details»
Cybrexa Therapeutics Presents Findings from First-in-Human
Oct 28, 2022 Cybrexa is a privately held clinical-stage biotechnology company pioneering novel antigen-independent tumor-targeting peptide drug conjugate (PDC) therapeutics. The …See details»
Cybrexa Therapeutics Announces First Patient Dosed with First-in …
Oct 7, 2024 Primary target patient population for the CBX-12 Phase 2 study is women with platinum-resistant or refractory ovarian cancer who are naïve to TOP1-targeted agents Study …See details»
Cybrexa Therapeutics Presents Findings from First-in-Human …
Oct 28, 2022 Cybrexa Therapeutics. Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studies. Results show early signs of efficacy with a favorable …See details»
Press Releases Archive - Cybrexa Therapeutics
November 01, 2022 04:06 PM Eastern Daylight Time – ALAMEDA, Calif. & NEW HAVEN, Conn.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) and Cybrexa Therapeutics …See details»
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting …
May 25, 2023 Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12 Cybrexa Therapeutics Thu, May 25, …See details»
News - Cybrexa Therapeutics
Latest news. We are passionate about how alphalex™ can improve cancer therapeutics. Read more about our impact and latest happenings.See details»
Cybrexa Therapeutics to Debut Preclinical Data Demonstrating …
Oct 10, 2023 Cybrexa Therapeutics. Preclinical Data Demonstrate CBX-15's Anti-Tumor Efficacy in Animal Models and Ability to Enhance Immunogenicity and Induce Immune Memory through …See details»
Our Technology - Cybrexa Therapeutics
How. By using technology that allows small molecule anti-cancer agents to penetrate cell membranes only at low pH, alphalex leverages the acidic tumor microenvironment to selectivSee details»